Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)

British Journal of Cancer

Volumn 103, Issue 8, 2010, Pages 1173-1181

  Van Herpen, C M L ^a   Mauer, M E ^b   Mesia, R ^c   Degardin, M ^d   Jelic, S ^e   Coens, C ^b   Betka, J ^f   Bernier, J ^g   Remenar, E ^h   Stewart, J S ⁱ   Preiss, J H ^j   Van Den Weyngaert, D ^k   Bottomley, A ^b   Vermorken, J B ^l  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d CENTRE OSCAR LAMBRET   (France)

^e INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^f UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^g CLINIQUE DE GENOLIER   (Switzerland)

^h NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

ⁱ CHARING CROSS HOSPITAL   (United Kingdom)

^j Caritasklinik St Theresia   (Germany)

^k MIDDELHEIM HOSPITAL   (Belgium)

^l ANTWERP UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

head and neck cancer; HRQOL; symptoms

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; ANTINEOPLASTIC AGENT; TAXOID;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; CARCINOMA, SQUAMOUS CELL; CONTROLLED STUDY; DISEASE COURSE; HEAD AND NECK NEOPLASMS; HEALTH STATUS; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE PROGRESSION; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HEALTH STATUS; HUMANS; QUALITY OF LIFE; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77958002438     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605860     Document Type: Article

References (30)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376
2. Abdel-Wahab M, Abitbol A, Lewin A, Troner M, Hamilton K, Markoe A (2005) Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma. Am J Clin Oncol 28: 359-366
3. Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck cancer. Lancet 371: 1695-1709
4. Bairati I, Meyer F, Gelinas M, Fortin A, Nabid A, Brochet F, Mercier JP, Tetu B, Harel F, Abdous B, Vigneault E, Vass S, Del VP, Roy J (2005) Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol 23: 5805-5813
5. Bentzen SM, Trotti A (2007) Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 25: 4096-4103
6. Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van PC, Curran D, Ahlner-Elmqvist M, Maher EJ, Meyza JW, Bredart A, Soderholm AL, Arraras JJ, Feine JS, Abendstein H, Morton RP, Pignon T, Huguenin P, Bottomly A, Kaasa S (2000) A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 36: 1796-1807
7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578
8. Chaplin JM, Morton RP (1999) A prospective, longitudinal study of pain in head and neck cancer patients. Head Neck 21: 531-537
9. Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, Jassem J, Baselga J, Rowinsky EK, Amellal N, Comte S, Bonner JA (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25: 2191-2197
10. de Graeff A, de Leeuw RJ, Ros WJ, Hordijk GJ, Battermann JJ, Blijham GH, Winnubst JA (1999) A prospective study on quality of life of laryngeal cancer patients treated with radiotherapy. Head Neck 21: 291-296
11. Dropkin MJ (1998) Disfigurement and dysfunction with head and neck cancer surgery. ORL Head Neck Nurs 16: 28-29
12. Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'haese S, Zurlo A (2003) Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials: does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 21: 3502-3511
13. Fakhry C, Gillison ML (2006) Clinical implications of human papilloma-virus in head and neck cancers. J Clin Oncol 24: 2606-2611
14. Fang FM, Tsai WL, Chien CY, Chiu HC, Wang CJ, Chen HC, Hsiung CY (2005) Changing quality of life in patients with advanced head and neck cancer after primary radiotherapy or chemoradiation. Oncology 68: 405-413
15. Fayers PM, Aaronson NK, Bjordal K (1999) EORTC QLQ-C30 Scoring Manual 9th edn EORTC: Brussels, Belgium
16. Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M, Moyer JS, Prince ME, Carey TE, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A (2010) Intensity-modulated chemoradiotherapy aiming to reduce dys-phagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol 28: 2732-2738
17. Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R (2002) Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 324: 1417
18. List MA, D'Antonio LL, Cella DF, Siston A, Mumby P, Haraf D, Vokes E (1996) The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale. A study of utility and validity.. Cancer 77: 2294-2301
19. Michiwaki Y, Schmelzeisen R, Hacki T, Michi K (1992) Articulatory function in glossectomized patients with immediate reconstruction using a free jejunum flap. J Craniomaxillofac Surg 20: 203-210
20. Nabell L, Spencer S (2003) Docetaxel with concurrent radiotherapy in head and neck cancer. Semin Oncol 30: 89-93
21. Nguyen NP, Frank C, Moltz CC, Vos P, Smith HJ, Karlsson U, Dutta S, Midyett A, Barloon J, Sallah S (2005) Impact of dysphagia on quality of life after treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys 61: 772-778
22. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16: 139-144
23. Pauloski BR, Logemann JA, Rademaker AW, McConnel FM, Stein D, Beery Q, Johnson J, Heiser MA, Cardinale S, Shedd D (1994) Speech and swallowing function after oral and oropharyngeal resections: one-year follow-up. Head Neck 16: 313-322
24. Pauloski BR, Rademaker AW, Logemann JA, Colangelo LA (1998) Speech and swallowing in irradiated and nonirradiated postsurgical oral cancer patients. Otolaryngol Head Neck Surg 118: 616-624
25. Rosenthal DI, Lewin JS, Eisbruch A (2006) Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 24: 2636-2643
26. Schrijvers D, van HC, Kerger J, Joosens E, Van Laer C, Awada A, van den Weyngaert D, Nguyen H, Le BBouder C, Castelijns JA, Kaanders J, De Mulder P, Vermorken JB (2004) Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol 15: 638-645
27. Scott NW, Fayers P, Bottomley A (2008) EORTC QLQ-C30 Reference Values Manual. EORTC Quality of Life Group publications: Brussels, Belgium
28. van Bokhorst-de van der Schuer M, van Leeuwen PA, Kuik DJ, Klop WM, Sauerwein HP, Snow GB, Quak JJ (1999) The impact of nutritional status on the prognoses of patients with advanced head and neck cancer. Cancer 86: 519-527
29. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357: 1695-1704
30. Young T, de Haes H, Fayers P (2002) Guidelines for Assessing Quality of Life in Clinical Trials 2nd edn EORTC Quality of Life Study Group Publications: Brussels, Belgium